BioTuesdays

Zenabis Q2 revenue jumps 115% from Q1

Zenabis Global (TSX:ZENA) posted second quarter gross revenue of $26.5-million, an increase of 115%, from $12.3-million in the first quarter of 2019. “We executed at or above plan in the second quarter and, in so...

Eloxx Pharma initiates Phase 2 cystinosis trial

Eloxx Pharmaceuticals (NASDAQ:ELOX) initiated a Phase 2 trial of ELX-02 for the treatment of nephropathic cystinosis. Cystinosis is a genetic disease caused by a mutation in the cystinosin gene, which limits production...